Alzheimer's

R&D

London’s life sciences scene upbeat as 2024 conference seaso...

With 2024 well under way, influential conferences in London have given a barometer reading on the conditions in the European biopharma market, reports Richard Staines.

Market Access

Aduhelm and an expensive failure to launch

Biogen’s treatment for Alzheimer’s was initially regarded as a major treatment breakthrough.

R&D

JP Morgan 2024 – Gene Kinney

Back at JP Morgan 2024, editor-in-chief Jonah Comstock caught u

R&D

Alzheimer’s drugs: An overview and update

When we covered JP Morgan in January, over and over we heard that neurodegenerative diseases, especially Alzheimer’s, were going to be one of the most exciting spaces in pharma this year.

Patients

Reuters Pharma USA 2023 - Ligia del Bianco

Reuters Pharma USA – Ligia Del Bianco

At Reuters Pharma USA last month in Philadelphia, centring the voice of the patient was a major topic of discussion throughout the event.

Patients

Nine for 2023, part two: healthcare’s hard problem, the prog...

The first part of IQVIA EMEA Thought Leadership’s Nine for 2023 three-part series, focusing on issues that will change the direction of healthcare and the pharmaceutical industry this year,